Sagittarius Life Science
Sagittarius Life Science Corp engages in the research, development, and sale of Chinese and western medicines, and health food products in Taiwan and Asia. It also offers organic food, daily necessities, and pet food; and engages in the research and development of biotechnology. Sagittarius Life Science Corp was founded in 1998 and is based in Taipei, Taiwan.
Sagittarius Life Science (3205) - Total Assets
Latest total assets as of September 2025: NT$1.11 Billion TWD
Based on the latest financial reports, Sagittarius Life Science (3205) holds total assets worth NT$1.11 Billion TWD as of September 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Sagittarius Life Science - Total Assets Trend (2015–2024)
This chart illustrates how Sagittarius Life Science’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Sagittarius Life Science - Asset Composition Analysis
Current Asset Composition (December 2024)
Sagittarius Life Science's total assets of NT$1.11 Billion consist of 48.3% current assets and 51.8% non-current assets.
| Asset Category | Amount (TWD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | NT$0.00 | 16.1% |
| Accounts Receivable | NT$43.33 Million | 8.3% |
| Inventory | NT$31.05 Million | 6.0% |
| Property, Plant & Equipment | NT$0.00 | 0.0% |
| Intangible Assets | NT$0.00 | 0.0% |
| Goodwill | NT$0.00 | 0.0% |
Asset Composition Trend (2015–2024)
This chart illustrates how Sagittarius Life Science's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Sagittarius Life Science's current assets represent 48.3% of total assets in 2024, a decrease from 85.9% in 2015.
- Cash Position: Cash and equivalents constituted 16.1% of total assets in 2024, down from 37.2% in 2015.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, a decrease from 2.0% in 2015.
- Asset Diversification: The largest asset category is accounts receivable at 8.3% of total assets.
Sagittarius Life Science Competitors by Total Assets
Key competitors of Sagittarius Life Science based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
MedPacto Inc
KQ:235980
|
Korea | ₩51.58 Billion |
|
2H0
F:2H0
|
Germany | €15.27 Million |
|
Shenzhen CAU Technology Co Ltd
SHE:000004
|
China | CN¥260.55 Million |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403
|
China | CN¥9.58 Billion |
|
Nanhua Bio Medicine Co Ltd
SHE:000504
|
China | CN¥841.96 Million |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518
|
China | CN¥509.14 Million |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
|
Hualan Biological EngineeringInc
SHE:002007
|
China | CN¥16.27 Billion |
Sagittarius Life Science - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Strong asset utilization - Sagittarius Life Science generates 0.90x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - Sagittarius Life Science is currently not profitable relative to its asset base.
Sagittarius Life Science - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 15.01 | 2.67 | 4.03 |
| Quick Ratio | 14.89 | 2.35 | 3.77 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | NT$801.04 Million | NT$ 164.71 Million | NT$ 381.60 Million |
Sagittarius Life Science - Advanced Valuation Insights
This section examines the relationship between Sagittarius Life Science's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 3.28 |
| Latest Market Cap to Assets Ratio | 0.11 |
| Asset Growth Rate (YoY) | -21.8% |
| Total Assets | NT$519.83 Million |
| Market Capitalization | $56.62 Million USD |
Valuation Analysis
Below Book Valuation: The market values Sagittarius Life Science's assets below their book value (0.11 x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Sagittarius Life Science's assets decreased by 21.8% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Sagittarius Life Science (2015–2024)
The table below shows the annual total assets of Sagittarius Life Science from 2015 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | NT$519.83 Million | -21.80% |
| 2023-12-31 | NT$664.72 Million | +14.78% |
| 2022-12-31 | NT$579.12 Million | -14.30% |
| 2021-12-31 | NT$675.75 Million | -8.77% |
| 2020-12-31 | NT$740.74 Million | -8.73% |
| 2019-12-31 | NT$811.59 Million | -9.19% |
| 2018-12-31 | NT$893.75 Million | -15.89% |
| 2017-12-31 | NT$1.06 Billion | -24.77% |
| 2016-12-31 | NT$1.41 Billion | +24.81% |
| 2015-12-31 | NT$1.13 Billion | -- |